Davis Polk advised the joint book-running managers in the offering. Adamas Pharmaceuticals, Inc. executed its $59 million follow-on offering of 14,375,000 shares of common stock, which included...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here